Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VRCA Stock Summary
Top 10 Correlated ETFs
VRCA
In the News
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023.
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
You want potential short-squeeze stocks that could have the bears running for cover? Great, we got ‘em right here!
Here's What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, biotechs were in focus among the notable insider purchases.
Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying
Ahead of the holiday weekend (and the end of the year), Berkshire Hathaway made another big buy of the Oracle of Omaha's favorite oil and gas exploration and production company.
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
Shares of Verrica Pharmaceuticals (NASDAQ: VRCA ) skyrocketed on Friday thanks to positive late-stage clinical trial results. Specifically, Verrica — along with its development and commercialization partner Torii Pharmaceutical — reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of molluscum contagiosum in Japan.
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023.
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted White, Verrica President and CEO, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 5:00 pm ET. The Company will also be participating in one-on-one meetings during the conference.
Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday
Verrica focuses on dermatology therapeutics. The company just received approval for its first marketed product.
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
WEST CHESTER, Pa., July 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company has entered into a non-binding term sheet for a term loan facility of up to $125 million, which the Company expects to close by the end of this week.
VRCA Financial details
VRCA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.44 | 0.27 | 0.11 | |
Net income per share | -1.12 | -1.82 | -1.44 | -0.81 | -1.48 | |
Operating cash flow per share | -1.1 | -1.21 | -1.02 | -0.55 | -0.85 | |
Free cash flow per share | -1.13 | -1.27 | -1.05 | -0.56 | -0.86 | |
Cash per share | 2.49 | 2.62 | 2.61 | 1.01 | 1.53 | |
Book value per share | 2.61 | 1.32 | 1.21 | 1.18 | 0.44 | |
Tangible book value per share | 2.61 | 1.32 | 1.21 | 1.18 | 0.44 | |
Share holders equity per share | 2.61 | 1.32 | 1.21 | 1.18 | 0.44 | |
Interest debt per share | 0.01 | 2.95 | 1.77 | 0.11 | 1.05 | |
Market cap | 395.63M | 287.7M | 247.18M | 93.53M | 331.91M | |
Enterprise value | 386.57M | 312.33M | 274.84M | 60.78M | 307.87M | |
P/E ratio | -14.15 | -6.32 | -6.35 | -3.38 | -4.95 | |
Price to sales ratio | 0 | 0 | 20.6 | 10.36 | 64.77 | |
POCF ratio | -14.43 | -9.52 | -8.96 | -5.01 | -8.6 | |
PFCF ratio | -14.08 | -9.08 | -8.68 | -4.93 | -8.52 | |
P/B Ratio | 6.09 | 8.72 | 7.58 | 2.34 | 16.79 | |
PTB ratio | 6.09 | 8.72 | 7.58 | 2.34 | 16.79 | |
EV to sales | 0 | 0 | 22.9 | 6.73 | 60.08 | |
Enterprise value over EBITDA | -12.85 | -7.87 | -8.93 | -2.91 | -4.93 | |
EV to operating cash flow | -14.1 | -10.34 | -9.96 | -3.26 | -7.98 | |
EV to free cash flow | -13.76 | -9.86 | -9.66 | -3.21 | -7.91 | |
Earnings yield | -0.07 | -0.16 | -0.16 | -0.3 | -0.2 | |
Free cash flow yield | -0.07 | -0.11 | -0.12 | -0.2 | -0.12 | |
Debt to equity | 0 | 2.15 | 1.33 | 0.04 | 2.2 | |
Debt to assets | 0 | 0.96 | 0.54 | 0.03 | 0.53 | |
Net debt to EBITDA | 0.3 | -0.62 | -0.9 | 1.57 | 0.39 | |
Current ratio | 19.39 | 1.66 | 1.61 | 11.31 | 4.55 | |
Interest coverage | 0 | -13.25 | -7.2 | -9.8 | -15.96 | |
Income quality | 0.97 | 0.71 | 0.79 | 0.76 | 0.58 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 2.25 | 1.93 | 0 | |
Research and developement to revenue | 0 | 0 | 1.33 | 1.35 | 3.96 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.05 | 0.03 | 0.02 | 0.01 | |
Capex to revenue | 0 | 0 | -0.07 | -0.03 | -0.07 | |
Capex to depreciation | -2.65 | -6.42 | -1.87 | -0.42 | -0.43 | |
Stock based compensation to revenue | 0 | 0 | 0.5 | 0.55 | 2.81 | |
Graham number | 8.12 | 7.35 | 6.26 | 4.64 | 3.81 | |
ROIC | -0.46 | -0.41 | -0.44 | -0.56 | -0.97 | |
Return on tangible assets | -0.41 | -0.61 | -0.49 | -0.62 | -0.82 | |
Graham Net | 2.35 | 0.97 | 0.85 | 0.87 | 0.25 | |
Working capital | 61.63M | 26M | 28.27M | 35.66M | 60.51M | |
Tangible asset value | 65.02M | 32.99M | 32.61M | 40.03M | 19.76M | |
Net current asset value | 61.57M | 24.3M | 26.81M | 34.43M | 15.7M | |
Invested capital | 0 | 2.15 | 1.33 | 0.04 | 2.2 | |
Average receivables | 0 | 0 | 0 | 243.5K | 2.45M | |
Average payables | 1.07M | 766.5K | 596.5K | 676K | 1.49M | |
Average inventory | 0 | 0 | 0 | -243.5K | 267.5K | |
Days sales outstanding | 0 | 0 | 0 | 19.68 | 314.57 | |
Days payables outstanding | 1.68K | 554.67 | 653.44 | 255.25 | 772.65 | |
Days of inventory on hand | 0 | 0 | 0 | -245.18 | 320.47 | |
Receivables turnover | 0 | 0 | 0 | 18.55 | 1.16 | |
Payables turnover | 0.22 | 0.66 | 0.56 | 1.43 | 0.47 | |
Inventory turnover | 0 | 0 | 0 | -1.49 | 1.14 | |
ROE | -0.43 | -1.38 | -1.19 | -0.69 | -3.39 | |
Capex per share | -0.03 | -0.06 | -0.03 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.06 | 0.04 | |
Net income per share | -0.14 | -0.14 | -0.24 | -0.54 | -0.53 | |
Operating cash flow per share | -0.12 | -0.11 | -0.1 | -0.32 | -0.32 | |
Free cash flow per share | -0.13 | -0.11 | -0.1 | -0.32 | -0.32 | |
Cash per share | 0.86 | 1.39 | 1.2 | 1.84 | 1.5 | |
Book value per share | 1.01 | 1.51 | 1.21 | 0.92 | 0.43 | |
Tangible book value per share | 1.01 | 1.51 | 1.21 | 0.92 | 0.43 | |
Share holders equity per share | 1.01 | 1.51 | 1.21 | 0.92 | 0.43 | |
Interest debt per share | 0.04 | 0.02 | 0.03 | 0.92 | 0.99 | |
Market cap | 109.22M | 279.65M | 264.94M | 178.44M | 339M | |
Enterprise value | 76.48M | 221.15M | 211.18M | 137.95M | 314.96M | |
P/E ratio | -4.83 | -11.48 | -6.03 | -1.8 | -3.44 | |
Price to sales ratio | 1.61K | 7.56K | 1.46K | 61.17 | 170.52 | |
POCF ratio | -22.05 | -60.93 | -56.74 | -12.05 | -23.01 | |
PFCF ratio | -21.76 | -60.78 | -56.04 | -11.99 | -22.66 | |
P/B Ratio | 2.73 | 4.31 | 4.78 | 4.22 | 17.15 | |
PTB ratio | 2.73 | 4.31 | 4.78 | 4.22 | 17.15 | |
EV to sales | 1.12K | 5.98K | 1.16K | 47.29 | 158.43 | |
Enterprise value over EBITDA | -12.89 | -34.24 | -19.45 | -5.77 | -15.45 | |
EV to operating cash flow | -15.44 | -48.18 | -45.23 | -9.31 | -21.38 | |
EV to free cash flow | -15.23 | -48.07 | -44.67 | -9.27 | -21.06 | |
Earnings yield | -0.05 | -0.02 | -0.04 | -0.14 | -0.07 | |
Free cash flow yield | -0.05 | -0.02 | -0.02 | -0.08 | -0.04 | |
Debt to equity | 0.04 | 0.02 | 0.02 | 1.04 | 2.2 | |
Debt to assets | 0.03 | 0.02 | 0.02 | 0.45 | 0.53 | |
Net debt to EBITDA | 5.52 | 9.06 | 4.95 | 1.69 | 1.18 | |
Current ratio | 11.31 | 23.87 | 9.91 | 8.06 | 4.55 | |
Interest coverage | 109 | 14.18 | 0 | 14.43 | -8.94 | |
Income quality | 0.84 | 0.7 | 0.42 | 0.6 | 0.6 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 46.9 | 116.73 | 32.62 | 6.87 | 15.25 | |
Research and developement to revenue | 44.56 | 74.03 | 31.46 | 2.23 | 2.68 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0.01 | 0 | 0.02 | |
Capex to revenue | -0.97 | -0.3 | -0.32 | -0.02 | -0.11 | |
Capex to depreciation | -0.17 | -0.08 | -0.44 | -0.18 | -1.05 | |
Stock based compensation to revenue | 17.22 | 29.57 | 8.48 | 3.31 | 1.04 | |
Graham number | 1.8 | 2.19 | 2.55 | 3.35 | 2.26 | |
ROIC | -0.14 | -0.1 | -0.21 | -0.27 | -0.32 | |
Return on tangible assets | -0.13 | -0.09 | -0.18 | -0.26 | -0.3 | |
Graham Net | 0.75 | 1.31 | 1.06 | 0.71 | 0.25 | |
Working capital | 35.66M | 60.45M | 51.05M | 80.35M | 60.51M | |
Tangible asset value | 40.03M | 64.85M | 55.4M | 42.3M | 19.76M | |
Net current asset value | 34.43M | 59.3M | 49.98M | 36.88M | 15.7M | |
Invested capital | 0.04 | 0.02 | 0.02 | 1.04 | 2.2 | |
Average receivables | 453K | 271.5K | 114.5K | 2.12M | 4.24M | |
Average payables | 322K | 541K | 1.32M | 1.99M | 2.19M | |
Average inventory | -243.5K | -243.5K | 0 | 139.5K | 650.5K | |
Days sales outstanding | 644.56 | 136.22 | 85.55 | 125.64 | 199.92 | |
Days payables outstanding | 735.97 | 761.03 | 1.36K | 1.19K | 582.81 | |
Days of inventory on hand | -706.94 | 0 | 0 | 173.17 | 241.73 | |
Receivables turnover | 0.14 | 0.66 | 1.05 | 0.72 | 0.45 | |
Payables turnover | 0.12 | 0.12 | 0.07 | 0.08 | 0.15 | |
Inventory turnover | -0.13 | 0 | 0 | 0.52 | 0.37 | |
ROE | -0.14 | -0.09 | -0.2 | -0.59 | -1.25 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
VRCA Frequently Asked Questions
What is Verrica Pharmaceuticals Inc. stock symbol ?
Verrica Pharmaceuticals Inc. is a US stock , located in West chester of Pa and trading under the symbol VRCA
Is Verrica Pharmaceuticals Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $10. The lowest prediction is $10 and the highest is $10
What is VRCA stock prediction ?
What is Verrica Pharmaceuticals Inc. stock quote today ?
Verrica Pharmaceuticals Inc. stock price is $5.91 today.
Is Verrica Pharmaceuticals Inc. stock public?
Yes, Verrica Pharmaceuticals Inc. is a publicly traded company.